KPV Peptide: Gut Inflammation and IBD Research Explained

What Is KPV?

KPV is a tripeptide — just three amino acids: Lysine-Proline-Valine. Despite its tiny size, it has attracted significant research attention for its anti-inflammatory properties. It is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino acid peptide produced naturally in the brain and adrenal glands that plays roles in pigmentation, feeding behaviour, and immune modulation.

While the full α-MSH molecule is large and has broad receptor effects, researchers have identified that the C-terminal tripeptide KPV retains much of α-MSH's anti-inflammatory activity in a more stable, smaller package. Its molecular weight of 342.43 Da and CAS number 69547-51-9 describe a compound that dissolves easily in aqueous solution and penetrates cell membranes — a critical feature given that its proposed mechanism is intracellular.

The Mechanism: Intracellular NF-κB Inhibition

The research interest in KPV centres on its ability to inhibit NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) — one of the master switches of the inflammatory response. NF-κB is a transcription factor that, when activated, moves from the cytoplasm into the cell nucleus and switches on the genes for pro-inflammatory cytokines including IL-1β, TNF-α, IL-6, and IL-8.

What makes KPV's mechanism distinctive is that it acts inside cells, directly blocking NF-κB's translocation to the nucleus. This contrasts with anti-inflammatory compounds that work at the cell surface (blocking receptors) or in the extracellular space. KPV's small size and positive charge allow it to enter cells and reach this intracellular target — a property most larger anti-inflammatory compounds don't have.

Key Research Areas

Gut Inflammation — IBD, Crohn's Disease, and UC Models

The most studied application for KPV is in models of inflammatory bowel disease (IBD). In rodent colitis models induced by DSS (dextran sodium sulphate) or TNBS (2,4,6-trinitrobenzene sulphonic acid) — the standard preclinical models for ulcerative colitis and Crohn's disease respectively — KPV administration has demonstrated:

• •Reduced colonic histological damage scores
• •Lower mucosal myeloperoxidase activity (a marker of neutrophil infiltration)
• •Decreased expression of IL-1β, TNF-α, and IL-6 in intestinal tissue
• •Improved intestinal barrier function by reducing epithelial permeability

Intestinal Barrier Repair

Inflammatory conditions disrupt the tight junctions between intestinal epithelial cells — the barrier that keeps gut bacteria and food particles from passing into the bloodstream. Research in cell culture models has shown KPV can reduce this permeability increase, supporting intestinal barrier integrity in inflammatory conditions.

Skin Wound Healing

KPV has also been studied in dermal wound models for its ability to reduce skin inflammation, support keratinocyte migration (cells that regenerate the skin surface), and accelerate re-epithelialisation. This mirrors BPC-157's wound healing research profile but through a different pathway.

Antimicrobial Activity

In in-vitro studies, KPV has demonstrated antimicrobial activity against common pathogens including Candida albicans and certain bacteria. This is consistent with α-MSH's known antimicrobial properties and adds an additional dimension to KPV's potential research applications in infection and inflammation models.

KPV vs BPC-157 for Gut Research

Both are available from Peptide Warehouse for separate or combined research protocols. They are complementary tools studying gut healing from different mechanistic angles.

Reconstitution and Storage

KPV is highly water-soluble due to its small size. Add 1–2mL of bacteriostatic water to the lyophilised vial and swirl gently — it dissolves rapidly. Store lyophilised at −20°C for up to 24 months. Store reconstituted solution at 2–8°C for up to 4 weeks. The solution should be clear and colourless.

Disclaimer: KPV is a research compound for in-vitro laboratory use only. Not for human consumption, therapeutic, or veterinary use. All information relates to preclinical research findings.